Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MedImmune
Gaithersburg*, Maryland*, USAmedimmune.com ↗
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Other
01
Overview
MedImmune developed and commercialized key biologics such as Synagis for RSV prevention and FluMist for influenza. It contributed a robust pipeline spanning infectious disease and oncology. Its technologies were foundational to AstraZeneca’s biologics R&D after the acquisition.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Vaccines (including live attenuated vaccines)Antibody-drug conjugates[8]
- Industry
- Biotech
02
Partnerships
Merck & Co.: AIDS/HIV monoclonal antibodies/vaccine development partnership in the early years.[1]NIH/DHHS contracts for pandemic flu vaccine development.[2]
Beyond the preview
Go deeper on MedImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedImmune.